Bristol Myers’ subcutaneous version of Opdivo gets earlier PDUFA date
The FDA has shortened the timeline for coming to a decision on Bristol Myers Squibb’s subcutaneous version of its blockbuster PD-1 inhibitor Opdivo. The company
The FDA has shortened the timeline for coming to a decision on Bristol Myers Squibb’s subcutaneous version of its blockbuster PD-1 inhibitor Opdivo. The company
Psilocybin found in mushrooms (often known as ‘magic’ mushrooms) has shown potential in treating depression. Credit: YARphotographer / Shutterstock A new study published in the
Cystic fibrosis (CF) is an autosomal recessive disease characterised by its effects on pancreatic function and persistent airway infections. Mutations in the CF transmembrane conductance